AIM ImmunoTech Inc. — Proxy Solicitation & Information Statement 2022

Oct 27, 2022

DEFA14A 1 formdefa14a.htm

Field: Rule-Page

Field: /Rule-Page

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 14A

Proxy Statement Pursuant to Section 14(a) of the

Securities Exchange Act of 1934

(Amendment No. )

Filed by the Registrant ☒

Filed by a Party other than the Registrant ☐

Check the appropriate box:

☐	Preliminary Proxy Statement
☐	Confidential, for Use of the Commission Only (as Permitted
by Rule 14a-6(e)(2))
☐	Definitive Proxy Statement
☒	Definitive Additional Materials
☐	Soliciting Material under § 240.14a-12

AIM ImmunoTech Inc.

(Name of Registrant as Specified in its Charter)

(Name of Person(s) Filing Proxy Statement, if other than the Registrant)

Payment of Filing Fee (Check all boxes that apply):

☒	No fee required
☐	Fee paid previously with
preliminary materials
☐	Fee computed on table in
exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11

Field: Rule-Page

Field: /Rule-Page

Field: Page; Sequence: 1

Field: /Page

On October 27, 2022, AIM ImmunoTech Inc. (the “Company”) posted the below message on Stocktwits.com and Yahoo! Finance:

We issued a letter to shareholders and encourage shareholders to read the letter, which can be found at https://www.businesswire.com/news/home/20221026006042/en/AIM-ImmunoTech-Board-Issues-Letter-to-Shareholders

Field: Page; Sequence: 4; Options: Last

Field: /Page